Tags: Drug.
Cerlapirdine (USAN; SAM-531 WAY-262531 PF-05212365) is a drug which is under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer’s disease and schizophrenia. As of 2011 it is in phase II clinical trials and has demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events. It exerts its effects by acting as a selective 5-HT6 receptor antagonist.
